Publications

  1. Najafova Z, Liu P, Wegwitz F, Ahmad M, Tamon L, Kosinsky RL, Xie W, Johnsen SA, Tuckermann J. RNF40 exerts stage-dependent functions in differentiating osteoblasts and is essential for bone cell crosstalk. Cell Death Differ. 2021 Feb; 28 (2):700-714 Epub 2020 Sept 08
    View PubMed
  2. Aseem SO, Jalan-Sakrikar N, Chi C, Navarro-Corcuera A, De Assuncao TM, Hamdan FH, Chowdhury S, Banales JM, Johnsen SA, Shah VH, Huebert RC. Epigenomic Evaluation of Cholangiocyte Transforming Growth Factor-beta Signaling Identifies a Selective Role for Histone 3 Lysine 9 Acetylation in Biliary Fibrosis. Gastroenterology. 2021 Feb; 160 (3):889-905.e10 Epub 2020 Oct 12
    View PubMed
  3. Koerdel K, Spitzner M, Meyer T, Engels N, Krause F, Gaedcke J, Conradi LC, Haubrock M, Beissbarth T, Leha A, Johnsen SA, Ghadimi BM, Rose-John S, Grade M, Wienands J. NOTCH Activation via gp130/STAT3 Signaling Confers Resistance to Chemoradiotherapy. Cancers (Basel). 2021 Jan 26; 13 (3)
    View PubMed
  4. Kutschat AP, Hamdan FH, Wang X, Wixom AQ, Najafova Z, Gibhardt CS, Kopp W, Gaedcke J, Strobel P, Ellenrieder V, Bogeski I, Hessmann E, Johnsen SA. STIM1 Mediates Calcium-dependent Epigenetic Reprogramming in Pancreatic Cancer. Cancer Res. 2021 Jan 12 [Epub ahead of print]
    View PubMed
  5. Oh-Hohenhorst SJ, Tilki D, Ahlers AK, Suling A, Hahn O, Tennstedt P, Matuszcak C, Maar H, Labitzky V, Hanika S, Starzonek S, Baumgart S, Johnsen SA, Kluth M, Sirma H, Simon R, Sauter G, Huland H, Schumacher U, Lange T. CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo. Cancer Gene Ther. 2021 Jan 7 Epub 2021 Jan 07
    View PubMed
  6. Zhang X, Zegar T, Weiser T, Hamdan FH, Berger BT, Lucas R, Balourdas DI, Ladigan S, Cheung PF, Liffers ST, Trajkovic-Arsic M, Scheffler B, Joerger AC, Hahn SA, Johnsen SA, Knapp S, Siveke JT. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma. Int J Cancer. 2020 Nov 15; 147 (10):2847-2861 Epub 2020 June 29
    View PubMed
  7. Patil S, Steuber B, Kopp W, Kari V, Urbach L, Wang X, Kuffer S, Bohnenberger H, Spyropoulou D, Zhang Z, Versemann L, Bosherz MS, Brunner M, Gaedcke J, Strobel P, Zhang JS, Neesse A, Ellenrieder V, Singh SK, Johnsen SA, Hessmann E. EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6. Cancer Res. 2020 Nov 1; 80 (21):4620-4632 Epub 2020 Sept 09
    View PubMed
  8. Wegwitz F, Prokakis E, Pejkovska A, Kosinsky RL, Glatzel M, Pantel K, Wikman H, Johnsen SA. The histone H2B ubiquitin ligase RNF40 is required for HER2-driven mammary tumorigenesis. Cell Death Dis. 2020 Oct 17; 11 (10):873
    View PubMed
  9. Wust HM, Wegener A, Frob F, Hartwig AC, Wegwitz F, Kari V, Schimmel M, Tamm ER, Johnsen SA, Wegner M, Sock E. Egr2-guided histone H2B monoubiquitination is required for peripheral nervous system myelination. Nucleic Acids Res. 2020 Sep 18; 48 (16):8959-8976
    View PubMed
  10. Lange T, Samatov TR, Galatenko VV, Steffen P, von Kriegstein H, Spethmann T, Wicklein D, Maar H, Kupfernagel K, Labitzky V, Hanika S, Starzonek S, Ahlers AK, Riecken K, Simon R, Polonski A, Sauter G, Schlomm T, Huland H, Johnsen SA, Schluter H, Tonevitsky AG, Schumacher U. Xenograft-derived mRNA/miR and protein interaction networks of systemic dissemination in human prostate cancer. Eur J Cancer. 2020 Sep; 137:93-107 Epub 2020 Aug 01
    View PubMed
  11. Wiese M, Hamdan FH, Kubiak K, Diederichs C, Gielen GH, Nussbaumer G, Carcaboso AM, Hulleman E, Johnsen SA, Kramm CM. Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells. Cell Death Dis. 2020 Aug 21; 11 (8):673
    View PubMed
  12. Xie W, Miehe M, Laufer S, Johnsen SA. The H2B ubiquitin-protein ligase RNF40 is required for somatic cell reprogramming. Cell Death Dis. 2020 Apr 27; 11 (4):287
    View PubMed
  13. Kosinsky RL, Zerche M, Saul D, Wang X, Wohn L, Wegwitz F, Begus-Nahrmann Y, Johnsen SA. USP22 exerts tumor-suppressive functions in colorectal cancer by decreasing mTOR activity. Cell Death Differ. 2020 Apr; 27 (4):1328-1340 Epub 2019 Sept 17
    View PubMed
  14. Kammoun M, Piquereau J, Nadal-Desbarats L, Meme S, Beuvin M, Bonne G, Veksler V, Le Fur Y, Pouletaut P, Meme W, Szeremeta F, Constans JM, Bruinsma ES, Nelson Holte MH, Najafova Z, Johnsen SA, Subramaniam M, Hawse JR, Bensamoun SF. Novel role of Tieg1 in muscle metabolism and mitochondrial oxidative capacities. Acta Physiol (Oxf). 2020 Mar; 228 (3):e13394 Epub 2019 Oct 19
    View PubMed
  15. Kosinsky RL, Helms M, Zerche M, Wohn L, Dyas A, Prokakis E, Kazerouni ZB, Bedi U, Wegwitz F, Johnsen SA. USP22-dependent HSP90AB1 expression promotes resistance to HSP90 inhibition in mammary and colorectal cancer. Cell Death Dis. 2019 Dec 4; 10 (12):911 Epub 2019 Dec 04
    View PubMed
  16. Flebbe H, Hamdan FH, Kari V, Kitz J, Gaedcke J, Ghadimi BM, Johnsen SA, Grade M. Epigenome Mapping Identifies Tumor-Specific Gene Expression in Primary Rectal Cancer. Cancers (Basel). 2019 Aug 9; 11 (8) Epub 2019 Aug 09
    View PubMed
  17. Schneider D, Chua RL, Molitor N, Hamdan FH, Rettenmeier EM, Prokakis E, Mishra VK, Kari V, Wegwitz F, Johnsen SA, Kosinsky RL. The E3 ubiquitin ligase RNF40 suppresses apoptosis in colorectal cancer cells. Clin Epigenetics. 2019 Jul 2; 11 (1):98 Epub 2019 July 02
    View PubMed
  18. Sen M, Wang X, Hamdan FH, Rapp J, Eggert J, Kosinsky RL, Wegwitz F, Kutschat AP, Younesi FS, Gaedcke J, Grade M, Hessmann E, Papantonis A, Strbel P, Johnsen SA. ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells. Clin Epigenetics. 2019 Jun 19; 11 (1):92 Epub 2019 June 19
    View PubMed
  19. Hasselluhn MC, Schmidt GE, Ellenrieder V, Johnsen SA, Hessmann E. Aberrant NFATc1 signaling counteracts TGFbeta-mediated growth arrest and apoptosis induction in pancreatic cancer progression. Cell Death Dis. 2019 Jun 6; 10 (6):446 Epub 2019 June 06
    View PubMed
  20. Hamdan FH, Johnsen SA. Perturbing Enhancer Activity in Cancer Therapy. Cancers (Basel). 2019 May 7; 11 (5) Epub 2019 May 07
    View PubMed
  21. Kosinsky RL, Chua RL, Qui M, Saul D, Mehlich D, Strobel P, Schildhaus HU, Wegwitz F, Faubion WA, Johnsen SA. Loss of RNF40 Decreases NF-kappaB Activity in Colorectal Cancer Cells and Reduces Colitis Burden in Mice. J Crohns Colitis. 2019 Mar 26; 13 (3):362-373
    View PubMed
  22. Patzak MS, Kari V, Patil S, Hamdan FH, Goetze RG, Brunner M, Gaedcke J, Kitz J, Jodrell DI, Richards FM, Pilarsky C, Gruetzmann R, Rummele P, Knosel T, Hessmann E, Ellenrieder V, Johnsen SA, Neesse A. Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites. EBioMedicine. 2019 Feb; 40:394-405 Epub 2019 Jan 30
    View PubMed
  23. Kari V, Raul SK, Henck JM, Kitz J, Kramer F, Kosinsky RL, Ubelmesser N, Mansour WY, Eggert J, Spitzner M, Najafova Z, Bastians H, Grade M, Gaedcke J, Wegwitz F, Johnsen SA. The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness. Clin Epigenetics. 2019 Jan 7; 11 (1):4 Epub 2019 Jan 07
    View PubMed
  24. Hamdan FH, Johnsen SA. DeltaNp63-dependent super enhancers define molecular identity in pancreatic cancer by an interconnected transcription factor network. Proc Natl Acad Sci U S A. 2018 Dec 26; 115 (52):E12343-E12352 Epub 2018 Dec 12
    View PubMed
  25. Kari V, Mansour WY, Raul SK, Baumgart SJ, Mund A, Grade M, Sirma H, Simon R, Will H, Dobbelstein M, Dikomey E, Johnsen SA. Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness. EMBO Rep. 2018 Oct; 19 (10)
    View PubMed
  26. Sriraman A, Dickmanns A, Najafova Z, Johnsen SA, Dobbelstein M. CDK4 inhibition diminishes p53 activation by MDM2 antagonists. Cell Death Dis. 2018 Sep 11; 9 (9):918 Epub 2018 Sept 11
    View PubMed
  27. Wroblewski M, Scheller-Wendorff M, Udonta F, Bauer R, Schlichting J, Zhao L, Ben Batalla I, Gensch V, Pasler S, Wu L, Wanior M, Taipaleenmaki H, Bolamperti S, Najafova Z, Pantel K, Bokemeyer C, Qi J, Hesse E, Knapp S, Johnsen S, Loges S. BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells. Haematologica. 2018 Jun; 103 (6):939-948 Epub 2018 Mar 22
    View PubMed
  28. Johnsen SA. Epigenetic Targeting of Aberrant Transcriptional Modulation in Pancreatic Cancer Epigenomes. 2018; 2(2):8.
  29. Iyer LM, Nagarajan S, Woelfer M, Schoger E, Khadjeh S, Zafiriou MP, Kari V, Herting J, Pang ST, Weber T, Rathjens FS, Fischer TH, Toischer K, Hasenfuss G, Noack C, Johnsen SA, Zelarayan LC. A context-specific cardiac beta-catenin and GATA4 interaction influences TCF7L2 occupancy and remodels chromatin driving disease progression in the adult heart. Nucleic Acids Res. 2018 Apr 6; 46 (6):2850-2867
    View PubMed
  30. Hessmann E, Patzak MS, Klein L, Chen N, Kari V, Ramu I, Bapiro TE, Frese KK, Gopinathan A, Richards FM, Jodrell DI, Verbeke C, Li X, Heuchel R, Lohr JM, Johnsen SA, Gress TM, Ellenrieder V, Neesse A. Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer. Gut. 2018 Mar; 67 (3):497-507 Epub 2017 Jan 10
    View PubMed
  31. Hamdan FH, Johnsen SA. Super enhancers - new analyses and perspectives on the low hanging fruit. Transcription. 2018; 9 (2):123-130 Epub 2017 Nov 03
    View PubMed
  32. Emons G, Spitzner M, Reineke S, Moller J, Auslander N, Kramer F, Hu Y, Beissbarth T, Wolff HA, Rave-Frank M, Hessmann E, Gaedcke J, Ghadimi BM, Johnsen SA, Ried T, Grade M. Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/beta-catenin Signaling. Mol Cancer Res. 2017 Nov; 15 (11):1481-1490 Epub 2017 Aug 15
    View PubMed
  33. Baumgart SJ, Najafova Z, Hossan T, Xie W, Nagarajan S, Kari V, Ditzel N, Kassem M, Johnsen SA. CHD1 regulates cell fate determination by activation of differentiation-induced genes. Nucleic Acids Res. 2017 Jul 27; 45 (13):7722-7735
    View PubMed
  34. Mishra VK, Wegwitz F, Kosinsky RL, Sen M, Baumgartner R, Wulff T, Siveke JT, Schildhaus HU, Najafova Z, Kari V, Kohlhof H, Hessmann E, Johnsen SA. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner. Nucleic Acids Res. 2017 Jun 20; 45 (11):6334-6349
    View PubMed
  35. Mishra VK, Subramaniam M, Kari V, Pitel KS, Baumgart SJ, Naylor RM, Nagarajan S, Wegwitz F, Ellenrieder V, Hawse JR, Johnsen SA. Kruppel-like Transcription Factor KLF10 Suppresses TGFbeta-Induced Epithelial-to-Mesenchymal Transition via a Negative Feedback Mechanism. Cancer Res. 2017 May 1; 77 (9):2387-2400 Epub 2017 Mar 01
    View PubMed
  36. Chen NM, Neesse A, Dyck ML, Steuber B, Koenig AO, Lubeseder-Martellato C, Winter T, Forster T, Bohnenberger H, Kitz J, Reuter-Jessen K, Griesmann H, Gaedcke J, Grade M, Zhang JS, Tsai WC, Siveke J, Schildhaus HU, Strobel P, Johnsen SA, Ellenrieder V, Hessmann E. Context-Dependent Epigenetic Regulation of Nuclear Factor of Activated T Cells 1 in Pancreatic Plasticity. Gastroenterology. 2017 May; 152 (6):1507-1520.e15 Epub 2017 Feb 08
    View PubMed
  37. Wiese M, Walther N, Diederichs C, Schill F, Monecke S, Salinas G, Sturm D, Pfister SM, Dressel R, Johnsen SA, Kramm CM. The beta-catenin/CBP-antagonist ICG-001 inhibits pediatric glioma tumorigenicity in a Wnt-independent manner. Oncotarget. 2017 Apr 18; 8 (16):27300-27313
    View PubMed
  38. Nagarajan S, Bedi U, Budida A, Hamdan FH, Mishra VK, Najafova Z, Xie W, Alawi M, Indenbirken D, Knapp S, Chiang CM, Grundhoff A, Kari V, Scheel CH, Wegwitz F, Johnsen SA. BRD4 promotes p63 and GRHL3 expression downstream of FOXO in mammary epithelial cells. Nucleic Acids Res. 2017 Apr 7; 45 (6):3130-3145
    View PubMed
  39. Xie W, Nagarajan S, Baumgart SJ, Kosinsky RL, Najafova Z, Kari V, Hennion M, Indenbirken D, Bonn S, Grundhoff A, Wegwitz F, Mansouri A, Johnsen SA. RNF40 regulates gene expression in an epigenetic context-dependent manner. Genome Biol. 2017 Feb 16; 18 (1):32
    View PubMed
  40. Hessmann E, Johnsen SA, Ellenrieder VE. Epigenetische Strategien in der Krebstherapie best practice onkologie. 2017; 2017(1).
  41. Najafova Z, Tirado-Magallanes R, Subramaniam M, Hossan T, Schmidt G, Nagarajan S, Baumgart SJ, Mishra VK, Bedi U, Hesse E, Knapp S, Hawse JR, Johnsen SA. BRD4 localization to lineage-specific enhancers is associated with a distinct transcription factor repertoire. Nucleic Acids Res. 2017 Jan 9; 45 (1):127-141 Epub 2016 Sept 19
    View PubMed
  42. Hessmann E, Johnsen SA, Siveke JT, Ellenrieder V. Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon? Gut. 2017 Jan; 66 (1):168-179 Epub 2016 Nov 03
    View PubMed
  43. Kari V, Mansour WY, Raul SK, Baumgart SJ, Mund A, Grade M, Sirma H, Simon R, Will H, Dobbelstein M, Dikomey E, Johnsen SA. Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness. EMBO Rep. 2016 Nov; 17 (11):1609-1623 Epub 2016 Sept 05
    View PubMed
  44. Dragoi D, Krattenmacher A, Mishra VK, Schmidt JM, Kloos UJ, Meixner LK, Hauck SM, Buggenthin F, Schwartz D, Marr C, Johnsen SA, Scheel CH. Twist1 induces distinct cell states depending on TGFBR1-activation. Oncotarget. 2016 May 24; 7 (21):30396-407
    View PubMed
  45. Hossan T, Nagarajan S, Baumgart SJ, Xie W, Magallanes RT, Hernandez C, Chiaroni PM, Indenbirken D, Spitzner M, Thomas-Chollier M, Grade M, Thieffry D, Grundhoff A, Wegwitz F, Johnsen SA. Histone Chaperone SSRP1 is Essential for Wnt Signaling Pathway Activity During Osteoblast Differentiation. Stem Cells. 2016 May; 34 (5):1369-76 Epub 2016 Feb 13
    View PubMed
  46. Schirmer MA, Luske CM, Roppel S, Schaudinn A, Zimmer C, Pfluger R, Haubrock M, Rapp J, Gungor C, Bockhorn M, Hackert T, Hank T, Strobel O, Werner J, Izbicki JR, Johnsen SA, Gaedcke J, Brockmoller J, Ghadimi BM. Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer. J Natl Cancer Inst. 2016 May; 108 (5) Epub 2016 Feb 08
    View PubMed
  47. Wiese M, Schill F, Sturm D, Pfister S, Hulleman E, Johnsen SA, Kramm CM. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3. Klin Padiatr. 2016 Apr; 228 (3):113-7 Epub 2016 May 02
    View PubMed
  48. Wienken M, Dickmanns A, Nemajerova A, Kramer D, Najafova Z, Weiss M, Karpiuk O, Kassem M, Zhang Y, Lozano G, Johnsen SA, Moll UM, Zhang X, Dobbelstein M. MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53. Mol Cell. 2016 Jan 7; 61 (1):68-83 Epub 2015 Dec 31
    View PubMed
  49. Kosinsky RL, Wegwitz F, Hellbach N, Dobbelstein M, Mansouri A, Vogel T, Begus-Nahrmann Y, Johnsen SA. Usp22 deficiency impairs intestinal epithelial lineage specification in vivo. Oncotarget. 2015 Nov 10; 6 (35):37906-18
    View PubMed
  50. Benito E, Urbanke H, Ramachandran B, Barth J, Halder R, Awasthi A, Jain G, Capece V, Burkhardt S, Navarro-Sala M, Nagarajan S, Schutz AL, Johnsen SA, Bonn S, Luhrmann R, Dean C, Fischer A. HDAC inhibitor-dependent transcriptome and memory reinstatement in cognitive decline models. J Clin Invest. 2015 Sep; 125 (9):3572-84 Epub 2015 Aug 17
    View PubMed
  51. Chen NM, Singh G, Koenig A, Liou GY, Storz P, Zhang JS, Regul L, Nagarajan S, Kuhnemuth B, Johnsen SA, Hebrok M, Siveke J, Billadeau DD, Ellenrieder V, Hessmann E. NFATc1 Links EGFR Signaling to Induction of Sox9 Transcription and Acinar-Ductal Transdifferentiation in the Pancreas. Gastroenterology. 2015 May; 148 (5):1024-1034.e9 Epub 2015 Jan 23
    View PubMed
  52. Werner S, Brors B, Eick J, Marques E, Pogenberg V, Parret A, Kemming D, Wood AW, Edgren H, Neubauer H, Streichert T, Riethdorf S, Bedi U, Baccelli I, Jucker M, Eils R, Fehm T, Trumpp A, Johnsen SA, Klefstrom J, Wilmanns M, Muller V, Pantel K, Wikman H. Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic Acid-induced 2. Cancer Discov. 2015 May; 5 (5):506-19 Epub 2015 Feb 25
    View PubMed
  53. Nitzki F, Tolosa EJ, Cuvelier N, Frommhold A, Salinas-Riester G, Johnsen SA, Fernandez-Zapico ME, Hahn H. Overexpression of mutant Ptch in rhabdomyosarcomas is associated with promoter hypomethylation and increased Gli1 and H3K4me3 occupancy. Oncotarget. 2015 Apr 20; 6 (11):9113-24
    View PubMed
  54. Nagarajan S, Benito E, Fischer A, Johnsen SA. H4K12ac is regulated by estrogen receptor-alpha and is associated with BRD4 function and inducible transcription. Oncotarget. 2015 Mar 30; 6 (9):7305-17
    View PubMed
  55. Bedi U, Scheel AH, Hennion M, Begus-Nahrmann Y, Ruschoff J, Johnsen SA. SUPT6H controls estrogen receptor activity and cellular differentiation by multiple epigenomic mechanisms. Oncogene. 2015 Jan 22; 34 (4):465-73 Epub 2014 Jan 20
    View PubMed
  56. Schmidt JM, Panzilius E, Bartsch HS, Irmler M, Beckers J, Kari V, Linnemann JR, Dragoi D, Hirschi B, Kloos UJ, Sass S, Theis F, Kahlert S, Johnsen SA, Sotlar K, Scheel CH. Stem-cell-like properties and epithelial plasticity arise as stable traits after transient Twist1 activation. Cell Rep. 2015 Jan 13; 10 (2):131-9 Epub 2015 Jan 08
    View PubMed
  57. Gaedcke J, Leha A, Claus R, Weichenhan D, Jung K, Kitz J, Grade M, Wolff HA, Jo P, Doyen J, Gerard JP, Johnsen SA, Plass C, Beissbarth T, Ghadimi M. Identification of a DNA methylation signature to predict disease-free survival in locally advanced rectal cancer. Oncotarget. 2014 Sep 30; 5 (18):8123-35
    View PubMed
  58. Nagarajan S, Hossan T, Alawi M, Najafova Z, Indenbirken D, Bedi U, Taipaleenmaki H, Ben-Batalla I, Scheller M, Loges S, Knapp S, Hesse E, Chiang CM, Grundhoff A, Johnsen SA. Bromodomain protein BRD4 is required for estrogen receptor-dependent enhancer activation and gene transcription. Cell Rep. 2014 Jul 24; 8 (2):460-9 Epub 2014 July 10
    View PubMed
  59. Mishra VK, Johnsen SA. Targeted therapy of epigenomic regulatory mechanisms controlling the epithelial to mesenchymal transition during tumor progression. Cell Tissue Res. 2014 Jun; 356 (3):617-30 Epub 2014 May 17
    View PubMed
  60. Bedi U, Mishra VK, Wasilewski D, Scheel C, Johnsen SA. Epigenetic plasticity: a central regulator of epithelial-to-mesenchymal transition in cancer. Oncotarget. 2014 Apr 30; 5 (8):2016-29
    View PubMed
  61. Jiao B, Taniguchi-Ishigaki N, Gungor C, Peters MA, Chen YW, Riethdorf S, Drung A, Ahronian LG, Shin J, Pagnis R, Pantel K, Tachibana T, Lewis BC, Johnsen SA, Bach I. Functional activity of RLIM/Rnf12 is regulated by phosphorylation-dependent nucleocytoplasmic shuttling. Mol Biol Cell. 2013 Oct; 24 (19):3085-96 Epub 2013 July 31
    View PubMed
  62. Zhang H, Park SH, Pantazides BG, Karpiuk O, Warren MD, Hardy CW, Duong DM, Park SJ, Kim HS, Vassilopoulos A, Seyfried NT, Johnsen SA, Gius D, Yu DS. SIRT2 directs the replication stress response through CDK9 deacetylation. Proc Natl Acad Sci U S A. 2013 Aug 13; 110 (33):13546-51 Epub 2013 July 29
    View PubMed
  63. Serebryanskaya TV, Yung T, Bogdanov AA, Shchebet A, Johnsen SA, Lyakhov AS, Ivashkevich LS, Ibrahimava ZA, Garbuzenco TS, Kolesnikova TS, Melnova NI, Gaponik PN, Ivashkevich OA. Synthesis, characterization, and biological evaluation of new tetrazole-based platinum(II) and palladium(II) chlorido complexes--potent cisplatin analogues and their trans isomers. J Inorg Biochem. 2013 Mar; 120:44-53 Epub 2012 Dec 13
    View PubMed
  64. Kari V, Karpiuk O, Tieg B, Kriegs M, Dikomey E, Krebber H, Begus-Nahrmann Y, Johnsen SA. A subset of histone H2B genes produces polyadenylated mRNAs under a variety of cellular conditions. PLoS One. 2013; 8 (5):e63745 Epub 2013 May 22
    View PubMed
  65. Prenzel T, Kramer F, Bedi U, Nagarajan S, Beissbarth T, Johnsen SA. Cohesin is required for expression of the estrogen receptor-alpha (ESR1) gene. Epigenetics Chromatin. 2012 Aug 22; 5 (1):13
    View PubMed
  66. Karpiuk O, Najafova Z, Kramer F, Hennion M, Galonska C, Konig A, Snaidero N, Vogel T, Shchebet A, Begus-Nahrmann Y, Kassem M, Simons M, Shcherbata H, Beissbarth T, Johnsen SA. The histone H2B monoubiquitination regulatory pathway is required for differentiation of multipotent stem cells. Mol Cell. 2012 Jun 8; 46 (5):705-13
    View PubMed
  67. Johnsen SA. The enigmatic role of H2Bub1 in cancer. FEBS Lett. 2012 Jun 4; 586 (11):1592-601 Epub 2012 Apr 13
    View PubMed
  68. Shchebet A, Karpiuk O, Kremmer E, Eick D, Johnsen SA. Phosphorylation by cyclin-dependent kinase-9 controls ubiquitin-conjugating enzyme-2A function. Cell Cycle. 2012 Jun 1; 11 (11):2122-7 Epub 2012 June 01
    View PubMed
  69. Johnsen SA. CDK9 and H2B monoubiquitination: a well-choreographed dance. PLoS Genet 2012; 8 (8):e1002860 Epub 2012 Aug 02
    View PubMed
  70. Kari V, Shchebet A, Neumann H, Johnsen SA. The H2B ubiquitin ligase RNF40 cooperates with SUPT16H to induce dynamic changes in chromatin structure during DNA double-strand break repair. Cell Cycle. 2011 Oct 15; 10 (20):3495-504
    View PubMed
  71. Prenzel T, Begus-Nahrmann Y, Kramer F, Hennion M, Hsu C, Gorsler T, Hintermair C, Eick D, Kremmer E, Simons M, Beissbarth T, Johnsen SA. Estrogen-dependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B. Cancer Res. 2011 Sep 1; 71 (17):5739-53 Epub 2011 Aug 23
    View PubMed
  72. Pirngruber J, Johnsen SA. Induced G1 cell-cycle arrest controls replication-dependent histone mRNA 3' end processing through p21, NPAT and CDK9. Oncogene. 2010 May 13; 29 (19):2853-63 Epub 2010 Mar 01
    View PubMed
  73. Buttner N, Johnsen SA, Kugler S, Vogel T. Af9/Mllt3 interferes with Tbr1 expression through epigenetic modification of histone H3K79 during development of the cerebral cortex. Proc Natl Acad Sci U S A. 2010 Apr 13; 107 (15):7042-7 Epub 2010 Mar 26
    View PubMed
  74. Haenssle HA, Korpas B, Hansen-Hagge C, Buhl T, Kaune KM, Johnsen S, Rosenberger A, Schon MP, Emmert S. Selection of patients for long-term surveillance with digital dermoscopy by assessment of melanoma risk factors. Arch Dermatol. 2010 Mar; 146 (3):257-64
    View PubMed
  75. Pirngruber J, Shchebet A, Johnsen SA. Insights into the function of the human P-TEFb component CDK9 in the regulation of chromatin modifications and co-transcriptional mRNA processing. Cell Cycle. 2009 Nov 15; 8 (22):3636-42 Epub 2009 Nov 24
    View PubMed
  76. Pirngruber J, Shchebet A, Schreiber L, Shema E, Minsky N, Chapman RD, Eick D, Aylon Y, Oren M, Johnsen SA. CDK9 directs H2B monoubiquitination and controls replication-dependent histone mRNA 3'-end processing. EMBO Rep. 2009 Aug; 10 (8):894-900 Epub 2009 July 03
    View PubMed
  77. Ecke I, Petry F, Rosenberger A, Tauber S, Monkemeyer S, Hess I, Dullin C, Kimmina S, Pirngruber J, Johnsen SA, Uhmann A, Nitzki F, Wojnowski L, Schulz-Schaeffer W, Witt O, Hahn H. Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. Cancer Res. 2009 Feb 1; 69 (3):887-95 Epub 2009 Jan 20
    View PubMed
  78. Johnsen SA, Gungor C, Prenzel T, Riethdorf S, Riethdorf L, Taniguchi-Ishigaki N, Rau T, Tursun B, Furlow JD, Sauter G, Scheffner M, Pantel K, Gannon F, Bach I. Regulation of estrogen-dependent transcription by the LIM cofactors CLIM and RLIM in breast cancer. Cancer Res. 2009 Jan 1; 69 (1):128-36
    View PubMed
  79. Shema E, Tirosh I, Aylon Y, Huang J, Ye C, Moskovits N, Raver-Shapira N, Minsky N, Pirngruber J, Tarcic G, Hublarova P, Moyal L, Gana-Weisz M, Shiloh Y, Yarden Y, Johnsen SA, Vojtesek B, Berger SL, Oren M. The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression. Genes Dev. 2008 Oct 1; 22 (19):2664-76
    View PubMed
  80. Waddell DS, Baehr LM, van den Brandt J, Johnsen SA, Reichardt HM, Furlow JD, Bodine SC. The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. Am J Physiol Endocrinol Metab. 2008 Oct; 295 (4):E785-97 Epub 2008 July 08
    View PubMed
  81. Subramaniam M, Hawse JR, Johnsen SA, Spelsberg TC. Role of TIEG1 in biological processes and disease states. J Cell Biochem. 2007 Oct 15; 102(3):539-48.
    View PubMed
  82. Johnsen SA, Kangaspeska S, Reid G, Gannon F. Interfering with the dynamics of estrogen receptor-regulated transcription. Ernst Schering Found Symp Proc. 2006; (1):1-12.
    View PubMed
  83. Tursun B, Schlüter A, Peters MA, Viehweger B, Ostendorff HP, Soosairajah J, Drung A, Bossenz M, Johnsen SA, Schweizer M, Bernard O, Bach I. The ubiquitin ligase Rnf6 regulates local LIM kinase 1 levels in axonal growth cones. [Erratum in Genes Dev 2005 Nov1;19(21):2643]. Genes Dev. 2005 Oct 1; 19(19):2307-19.
    View PubMed
  84. Effenberger KE, Johnsen SA, Monroe DG, Spelsberg TC, Westendorf JJ. Regulation of osteoblastic phenotype and gene expression by hop-derived phytoestrogens. J Steroid Biochem Mol Biol. 2005 Sep; 96(5):387-99. Epub 2005 Jul 12.
    View PubMed
  85. Subramaniam M, Gorny G, Johnsen SA, Monroe DG, Evans GL, Fraser DG, Rickard DJ, Rasmussen K, van Deursen JM, Turner RT, Oursler MJ, Spelsberg TC. TIEG1 null mouse-derived osteoblasts are defective in mineralization and in support of osteoclast differentiation in vitro. Mol Cell Biol. 2005 Feb; 25 (3):1191-9
    View PubMed
  86. Reinholz MM, An MW, Johnsen SA, Subramaniam M, Suman VJ, Ingle JN, Roche PC, Spelsberg TC. Differential gene expression of TGF beta inducible early gene (TIEG), Smad7, Smad2 and Bard1 in normal and malignant breast tissue. Breast Cancer Res Treat. 2004 Jul; 86: (1)75-88.
    View PubMed
  87. Johnsen SA, Subramaniam M, Effenberger KE, Spelsberg TC. The TGF beta inducible early gene plays a central role in the anti-proliferative response to TGF beta. Signal Transduction. 2004; 4(1-2):29-35.
  88. Monroe DG, Getz BJ, Johnsen SA, Riggs BL, Khosla S, Spelsberg TC. Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERalpha or ERbeta. J Cell Biochem. 2003 Oct 1; 90(2):315-26.
    View PubMed
  89. Monroe DG, Johnsen SA, Subramaniam M, Getz BJ, Khosla S, Riggs BL, Riggs BL, Spelsberg TC. Mutual antagonism of estrogen receptors alpha and beta and their preferred interactions with steroid receptor coactivators in human osteoblastic cell lines. J Endocrinol. 2003 Mar; 176 (3):349-57
    View PubMed
  90. Johnsen SA, Subramaniam M, Monroe DG, Janknecht R, Spelsberg TC. Modulation of transforming growth factor beta (TGFbeta)/Smad transcriptional responses through targeted degradation of TGFbeta-inducible early gene-1 by human seven in absentia homologue. J Biol Chem. 2002 Aug 23; 277 (34):30754-9 Epub 2002 June 18
    View PubMed
  91. Johnsen SA, Subramaniam M, Janknecht R, Spelsberg TC. TGF beta inducible early gene enhances TGF beta/Smad-dependent transcriptional responses. Oncogene. 2002 Aug 22; 21(37):5783-90.
    View PubMed
  92. Johnsen SA, Subramaniam M, Katagiri T, Janknecht R, Spelsberg TC. Transcriptional regulation of Smad2 is required for enhancement of TGF beta/Smad signaling by TGF beta inducible early gene. J Cell Biochem. 2002; 87(2):233-41.
    View PubMed
  93. Hefferan TE, Reinholz GG, Rickard DJ, Johnsen SA, Waters KM, Subramaniam M, Spelsberg TC. Overexpression of a nuclear protein, TIEG, mimics transforming growth factor-beta action in human osteoblast cells. J Biol Chem. 2000 Jul 7; 275 (27):20255-9
    View PubMed